
Mina Nikanjam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/982311/publications.pdf Version: 2024-02-01



MINA NIKANIAM

#	Article	IF	CITATIONS
1	Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations , 2022, 5, .		0
2	Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Molecular Oncology, 2021, 15, 67-79.	4.6	28
3	Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. Clinical Pharmacology and Therapeutics, 2021, 109, 184-192.	4.7	6
4	S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults. European Journal of Clinical Pharmacology, 2021, 77, 1349-1356.	1.9	1
5	<i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. Molecular Cancer Therapeutics, 2021, 20, 1072-1079.	4.1	6
6	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naÃ ⁻ ve study. Genome Medicine, 2021, 13, 155.	8.2	44
7	Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‣1 expression in cancer patients. International Journal of Cancer, 2020, 146, 3087-3097.	5.1	20
8	Targeting fusions for improved outcomes in oncology treatment. Cancer, 2020, 126, 1315-1321.	4.1	14
9	Development and preclinical pharmacology of a novel dCK inhibitor, DI-87. Biochemical Pharmacology, 2020, 172, 113742.	4.4	8
10	Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nature Communications, 2020, 11, 4965.	12.8	172
11	Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncolmmunology, 2020, 9, 1781997.	4.6	8
12	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncolmmunology, 2020, 9, 1708065.	4.6	41
13	Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treatment Reviews, 2020, 86, 102019.	7.7	327
14	Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Oncolmmunology, 2020, 9, 1710052.	4.6	17
15	Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. EJNMMI Research, 2020, 10, 150.	2.5	9
16	Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy. Cureus, 2020, 12, e8967.	0.5	2
17	Population pharmacokinetics of siltuximab: impact of disease state. Cancer Chemotherapy and Pharmacology, 2019, 84, 993-1001.	2.3	6
18	Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemotherapy and Pharmacology, 2019, 84, 1339-1348.	2.3	33

Mina Nikanjam

#	Article	IF	CITATIONS
19	Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemotherapy and Pharmacology, 2018, 81, 171-178.	2.3	21
20	New Rationales and Designs for Clinical Trials in the Era of Precision Medicine. , 2018, , 30-30.		0
21	Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. Journal of Clinical Pharmacology, 2018, 58, 1604-1617.	2.0	11
22	Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience. Cureus, 2018, 10, e3634.	0.5	0
23	Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. Oncologist, 2017, 22, 576-584.	3.7	39
24	ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. Nature Communications, 2017, 8, 241.	12.8	44
25	Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. Oncolmmunology, 2017, 6, e1338997.	4.6	29
26	Dosing targeted and cytotoxic twoâ€drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. International Journal of Cancer, 2016, 139, 2135-2141.	5.1	31
27	Dosing <i>de novo</i> combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget, 2016, 7, 11310-11320.	1.8	50